csirt@kutim:~/threat-intel/cve/CVE-2026-76236

Katalog CVE

CVSS 7.2 · High EPSS 0,36%

Kerentanan Authorization Bypass Through User-Controlled Key. Skor CVSS 4.0 7.2 (High) menurut vulncheck.com.

Deskripsi (NVD)

stigmem-node before 0.9.0a12 contains a cross-tenant broken object level authorization (BOLA) flaw in the RTBF (right-to-be-forgotten) tombstone mechanism. issue_tombstone defaulted the tenant to "default" instead of the caller's tenant, allowing deletion records to be written to the wrong tenant, and the read-suppression path (_get_tombstone_filter and the tombstone scope cache) lacked a tenant_id predicate, so tombstone suppression was applied tenant-blind across fact queries and provenance reads. As a result, a tenant's deletion could be attributed to the wrong tenant and tombstone suppression could either hide facts belonging to other tenants or fail to hide facts within the correct tenant, undermining data isolation and RTBF guarantees. The issue is exploitable only on multi-tenant deployments running the opt-in stigmem-plugin-multi-tenant; single-tenant deployments are unaffected. Fixed in 0.9.0a12.

Rincian

Terbit di NVD
19 Agustus 2026
Terakhir diubah
11 September 2026
Status NVD
Deferred
CVSS 4.0
7.2 (High), sumber vulncheck.com
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:H/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-639: Authorization Bypass Through User-Controlled Key
EPSS (30 hari)
0,36% peluang dieksploitasi; lebih tinggi dari 28,4% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.